



Stepwise Approach: 5-11 years

2020 EPR 3 Updates/GINA Hybrid



At every visit, check inhaler technique, medication adherence, and assess for environmental changes.



Stepwise Approach: 5-11 years

Additional Notes



Alternative Reliever Therapy at Steps 3-5

Consider **SMART** (Single Maintenance and Reliever Therapy) in consultation with a specialist

ICS + Formoterol PRN

- 4 puffs at a time, max 8 puffs per day for maintenance + reliever



At every visit:

- check inhaler technique
- check medication adherence
- assess any changes in environment



Consider consult with asthma specialist at **Steps 2 and 3**

Recommend consult with asthma specialist at **Steps 4, 5, and 6**



Montelukast has an **FDA Boxed Warning** due to risk of serious adverse neuropsychiatric side effects and is no longer recommended as an asthma controller medication.

Abbreviations

EPR 3

Expert Panel Report 3

GINA

Global Initiative for Asthma

PRN

As Needed

ICS

Inhaled Corticosteroids

URI

Upper Respiratory Infection

LABA

Long-Acting Beta-Agonist

LAMA

Long-Acting Muscarinic Antagonist

OCS

Oral Corticosteroid